Business Wire

VA-REGULA

Share
Regula Responds to Forensic Experts' Needs with Fast and Intuitive Operating Software

Regula, a global developer of forensic devices and identity verification solutions, has released a significant update to its operating software, Regula Forensic Studio. This major revamp enhances the functionality of forensic devices, improves usability, streamlines operations, and allows for more precise document examination.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240702630951/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

A forensic expert examines a banknote with the help of a Regula device and Regula Forensic Studio software (Photo: Regula) 

Compatible with Regula’s most recent advanced forensic devices, including the company’s flagship dual-video spectral comparator, Regula 4308, Regula Forensic Studio software facilitates manual examination of handwritten texts, banknotes, travel and identity documents, collectibles, and more. Supplied in a bundle with forensic devices and available out-of-the-box, Regula Forensic Studio can operate all Regula devices in a forensic laboratory, creating a smooth user experience and allowing for a wide range of examinations.

The new features and improvements in Regula Forensic Studio significantly elevate the user experience, as well as the convenience, speed, and accuracy of forensic examination.

Crucial examination speed and precision enhancements include:

  • A new cross-platform architecture that significantly streamlines document processing and reporting, and ensures full compatibility with all popular operating systems, such as Windows, Linux, and macOS.
  • The possibility of creating predefined scenarios (macros) for repetitive tasks, which makes it possible to automate the verification process for certain types of documents. For example, if an expert needs to verify a wad of banknotes, they can automatically record the sequence of checks (including all the lighting and filtering techniques) for one banknote, and auto-repeat it for the rest of the wad. Not only does this feature streamline the whole process, but also eliminates human-related errors.
  • Fully automated ID verification in mere seconds through seamless integration with Regula Document Reader SDK, which instantly recognizes the document type and validates all its data from MRZs, RFID chips, barcodes, and performs available security checks.
  • Enhanced integration with the Information Reference System (IRS), which makes it simple to compare an examined document to its reference image from the database. Thanks to real-time sync between RFS and the Information Reference System, the device's active light source is switched to the one used in the reference sample, and vice versa. This leads to more quick and efficient examinations.
  • Automated banknote residual area measurement, a new feature that was added as a response to customers’ needs. It uses banknote references from the Regula IRS to automatically measure the undamaged area of a banknote and determine if it can be accepted by the bank.

Key usability enhancements include:

  • A new intuitive user-friendly interface.
  • Multi-screen support to allow users to drag and drop application tabs between monitors, which is especially convenient when working with several images.
  • Colored image superimposition, a new feature that highlights different elements of two images for easier comparison.
  • Pseudocolor visualization, a feature that uses substitute bright colors to highlight areas within the same color (like some indistinguishable shades of gray) for better visualization.
  • Automatic detection of Machine Identification Code (MIC), a new feature that detects a unique yellow-dot pattern color laser printers and copiers leave on paper sheets. This helps identify the source of printed documents.

“In the crowded field of ID verification, Regula has distinguished itself by constantly improving, as well as adopting a customer-centric approach at the core of our research and development. The updated Regula Forensic Studio software has become notably faster and more efficient. It reflects feedback from external forensic experts and our customers, and incorporates features designed to address specific use cases and improve operations. This user-centric approach helps us boost the functionality of our solutions and meet the evolving needs of our customers in the most efficient way,” says Ihar Kliashchou, Chief Technology Officer at Regula.

To see the full list of new features and capabilities and learn more about the recent update of Regula Forensic Studio, please visit Regula’s website.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.

Learn more at www.regulaforensics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240702630951/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye